This patient-level pooled analysis used data from 30 827 participants at risk of HF and showed that aspirin use was associated with a higher risk of incident fatal and non-fatal HF.
An exploratory analysis of the PARADISE-MI trial suggested that treatment with sacubitril/valsartan after an acute MI may reduce recurrent HF events compared to ramipril.
AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.
Treatment with cagrilintide for 26 weeks in individuals with overweight or obesity without T2DM resulted in dose-dependent reduction in bodyweight and waist circumference.
AHA 2021 Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.
The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.
What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.
The use of race in equations to estimate GFR is a subject of discussion. This study developed new eGFR equations that do not include race and compared the performance of current and new eGFR equations.
AHA 2021 An interim analysis of the REVERSE-IT study showed that administration of bentracimab resulted in immediate and sustained reversal of antiplatelet effect of ticagrelor in patients who present with uncontrolled major or life-threating bleeding or who require urgent surgery or invasive procedures.
AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.
AHA 2021 In a dose-ranging phase 2 study, ≥100 mg per day of the oral factor XIa inhibitor milvexian reduced VTE rate compared to enoxaparin in patients who underwent elective knee replacement surgery.